Yu-Ning Wong
Datos Biográficos
| ID | 5537576 |
|---|---|
| NOMBRE | Yu-Ning Wong |
| NOMBRES | Yu-Ning |
| APELLIDO | Wong |
| FIRMA | WONG Y |
| AFILIACIONES | Fox Chase Cancer Center |
| VERIFICADO | No |
| TOTAL DE OBRAS | 5 |
| TOTAL DE CITAS | 0 |
| TOTAL COMO AUTOR | 5 |
| TOTAL COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2011 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2017 |
| ÍNDICE H | 0 |
Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer
BACKGROUND: Targeted therapy for patients with lung and colon cancer based on tumor molecular profiles is an important cancer treatment strategy, but the impact of gene mutation tests on cancer treatment and outcomes in large populations is not clear. In this study, we assessed the accuracy of an algorithm to identify tumor mutation testing in administrative claims data during a period before test-specific Current Procedural Terminology codes wer…
Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data
BACKGROUND AND OBJECTIVES: The paradoxical rise in overall and cancer-specific mortality despite increased detection and treatment of renal cell carcinoma (RCC) is termed "treatment disconnect." We reassess this phenomenon by evaluating impact of missing data and rising incidence on mortality trends. RESEARCH DESIGN, SUBJECTS, AND MEASURES: Using Surveillance, Epidemiology, and End Results data, we identified patients with RCC diagnosis from 1973…
Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work
BACKGROUND: Comorbidity adjustment is an important component of health services research and clinical prognosis. When adjusting for comorbidities in statistical models, researchers can include comorbidities individually or through the use of summary measures such as the Charlson Comorbidity Index or Elixhauser score. We examined the conditions under which individual versus summary measures are most appropriate. METHODS: We provide an analytic pro…
Cancer Patients’ Trade-offs Among Efficacy, Toxicity, and Out-of-Pocket Cost in the Curative and Noncurative Setting
BACKGROUND: When making treatment decisions, cancer patients must make trade-offs among efficacy, toxicity, and cost. However, little is known about what patient characteristics may influence these trade-offs. METHODS: A total of 400 cancer patients reviewed 2 of 3 stylized curative and noncurative scenarios that asked them to choose between 2 treatments of varying levels of efficacy, toxicity, and cost. Each scenario included 9 choice sets. Demo…
Racial Disparities in Changing to a High-volume Urologist Among Men With Localized Prostate Cancer
BACKGROUND: Patients who receive surgery from high-volume surgeons tend to have better outcomes. Black patients, however, are less likely to receive surgery from high-volume surgeons. OBJECTIVE: Among men with localized prostate cancer, we examined whether disparities in use of high-volume urologists resulted from racial differences in patients being diagnosed by high-volume urologists and/or changing to high-volume urologists for surgery. RESEAR…
Sin obras prominentes en esta página.
Racial Disparities in Changing to a High-volume Urologist Among Men With Localized Prostate Cancer
BACKGROUND: Patients who receive surgery from high-volume surgeons tend to have better outcomes. Black patients, however, are less likely to receive surgery from high-volume surgeons. OBJECTIVE: Among men with localized prostate cancer, we examined whether disparities in use of high-volume urologists resulted from racial differences in patients being diagnosed by high-volume urologists and/or changing to high-volume urologists for surgery. RESEAR…
Cancer Patients’ Trade-offs Among Efficacy, Toxicity, and Out-of-Pocket Cost in the Curative and Noncurative Setting
BACKGROUND: When making treatment decisions, cancer patients must make trade-offs among efficacy, toxicity, and cost. However, little is known about what patient characteristics may influence these trade-offs. METHODS: A total of 400 cancer patients reviewed 2 of 3 stylized curative and noncurative scenarios that asked them to choose between 2 treatments of varying levels of efficacy, toxicity, and cost. Each scenario included 9 choice sets. Demo…
Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work
BACKGROUND: Comorbidity adjustment is an important component of health services research and clinical prognosis. When adjusting for comorbidities in statistical models, researchers can include comorbidities individually or through the use of summary measures such as the Charlson Comorbidity Index or Elixhauser score. We examined the conditions under which individual versus summary measures are most appropriate. METHODS: We provide an analytic pro…
Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer
BACKGROUND: Targeted therapy for patients with lung and colon cancer based on tumor molecular profiles is an important cancer treatment strategy, but the impact of gene mutation tests on cancer treatment and outcomes in large populations is not clear. In this study, we assessed the accuracy of an algorithm to identify tumor mutation testing in administrative claims data during a period before test-specific Current Procedural Terminology codes wer…
Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data
BACKGROUND AND OBJECTIVES: The paradoxical rise in overall and cancer-specific mortality despite increased detection and treatment of renal cell carcinoma (RCC) is termed "treatment disconnect." We reassess this phenomenon by evaluating impact of missing data and rising incidence on mortality trends. RESEARCH DESIGN, SUBJECTS, AND MEASURES: Using Surveillance, Epidemiology, and End Results data, we identified patients with RCC diagnosis from 1973…
Medicine (5 obras) · Internal Medicine (4 obras) · Internal Medicine (4 obras) · Cancer (3 obras) · Confounding (2 obras) · Demography (2 obras) · Epidemiology (2 obras) · Epidemiology (2 obras) · Oncology (2 obras) · Oncology (2 obras)